Mark S. Dykewicz

TL;DR: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR, addressing the relative merits of using oral H1‐antihistamines, intranasal H1-antihistsamines, IntranasAL corticosteroids, and leukotriene receptor antagonists either alone or in combination.

TL;DR: This document incorporated the efforts of many participants, and no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters.

TL;DR: The document emphasizes the importance of rhinitis management for comorbid conditions (asthma, sinusitis, otitis media) and when consultation with an allergist-immunologist should be considered.

TL;DR: Treatment of chronic rhinosinusitis is less straightforward because only some chronic sinusitis cases have an infectious basis, and a variety of medical and surgical approaches might be required.

TL;DR: Better identification of endotypes might permit individualization of therapy that can be targeted against the pathophysiologic processes of a patient's endotype, with potential for more effective treatment and better patient outcomes.